Resveratrol is one of the most recognized names in longevity supplementation — backed by a decade of high-profile research, several famous advocates, and a compelling story about red wine and aging. Pterostilbene is its lesser-known structural cousin: a compound from blueberries that shares resveratrol’s core mechanisms but behaves differently in the body in ways that matter for supplementation.
This article compares the two compounds directly — on chemistry, bioavailability, mechanisms, research evidence, safety, dosing, and how to decide which one to use. If you are already familiar with resveratrol and want to understand whether pterostilbene is worth adding or substituting, this is the comparison you need.
The Chemistry: What Makes These Two Compounds Different
Resveratrol and pterostilbene belong to the stilbenoid family of polyphenols. They share the same basic molecular backbone — two phenol rings connected by a double bond — but differ in their side groups. Resveratrol has three hydroxyl (–OH) groups. Pterostilbene has two of those hydroxyl groups replaced by methoxy (–OCH₃) groups.
That structural difference sounds minor. Its practical consequences are not. The methoxy groups make pterostilbene significantly more lipophilic (fat-soluble), which improves its ability to cross cell membranes and, critically, to survive the digestive process without being metabolized into less active compounds before it reaches systemic circulation.
In short: pterostilbene and resveratrol are similar enough to share most of the same biological targets, but pterostilbene gets there more reliably.
Bioavailability: The Core Difference
This is where the comparison becomes most practically relevant. Resveratrol has notoriously poor oral bioavailability. Despite being absorbed in the gut, it is rapidly and extensively metabolized — primarily by sulfation and glucuronidation in the intestinal wall and liver — resulting in very little intact resveratrol reaching systemic circulation. Studies have found that the bioavailability of standard resveratrol formulations can be as low as 1%, with most absorbed resveratrol appearing in the bloodstream as conjugated metabolites rather than the active parent compound.
Pterostilbene fares considerably better. The methoxy substitutions reduce its susceptibility to phase II metabolism, allowing more of the intact compound to enter circulation. Research by Kapetanovic et al. (2011) in Cancer Chemoprevention Research found pterostilbene bioavailability in rats was approximately 80%, compared to roughly 20% for resveratrol under comparable conditions. Human pharmacokinetic studies, including work by Zabarska et al. and a clinical trial published by Riche et al. (2013) in the Journal of Toxicology, confirm meaningfully higher plasma concentrations from comparable pterostilbene doses relative to resveratrol.
Pterostilbene also has a longer half-life — estimated at around 105 minutes versus approximately 14 minutes for resveratrol — meaning it remains active in the body for a longer window after dosing.
The practical implication: a 50–100 mg dose of pterostilbene may deliver more bioactive compound to target tissues than a 500 mg dose of standard resveratrol. This does not mean pterostilbene is definitively superior in outcome — resveratrol’s metabolites are not entirely inactive — but bioavailability is a meaningful factor when comparing the two.
Because of their structural similarity, resveratrol and pterostilbene act on many of the same cellular targets. Understanding these helps clarify why both belong in conversations about longevity.
Sirtuin Activation
Both compounds activate SIRT1, the NAD+-dependent deacetylase at the center of the sirtuin longevity pathway. SIRT1 regulates gene expression, DNA repair, mitochondrial biogenesis, and stress response. The activation by polyphenols like resveratrol was the foundation of David Sinclair’s STAC (sirtuin-activating compound) hypothesis, which generated enormous interest in resveratrol through the mid-2000s. Whether stilbenes activate sirtuins directly or indirectly (by modulating NAD+ availability or upstream pathways) remains debated, but the functional effects on sirtuin-regulated processes are well-documented in cell and animal studies. For a deeper look at this pathway, see the article on the sirtuin theory of aging.
AMPK Activation
Both compounds activate AMPK, the cellular energy sensor that promotes fat oxidation, mitochondrial biogenesis, and autophagy while inhibiting anabolic processes associated with accelerated aging. AMPK activation broadly overlaps with the metabolic effects of calorie restriction and exercise — a recurring theme in longevity compound research. The relationship between NAD+, sirtuins, and AMPK is covered in more detail in the article on sirtuins, AMPK, and mTOR.
Anti-Inflammatory Activity
Both stilbenes inhibit NF-κB signaling and reduce pro-inflammatory cytokine production — including IL-6, TNF-alpha, and COX-2-mediated prostaglandins. This anti-inflammatory activity is a shared property with most polyphenols, but stilbenes appear to be particularly active in this regard compared to their structural peers.
Antioxidant and Mitochondrial Effects
Both compounds reduce oxidative stress, upregulate endogenous antioxidant enzymes, and show evidence of supporting mitochondrial function in cell and animal models. The mitochondrial effects are likely downstream of AMPK and SIRT1 activation rather than direct antioxidant scavenging.
Where the Research Diverges
Despite shared mechanisms, the bodies of research behind these compounds are not equivalent — in volume, type, or direction.
Resveratrol: More Human Data, More Controversy
Resveratrol has been studied extensively in human clinical trials, primarily for metabolic and cardiovascular outcomes. The results are mixed. Some trials show meaningful improvements in insulin sensitivity, blood pressure, and inflammatory markers in metabolically compromised populations. Others — including a high-profile 2012 JAMA Internal Medicine paper by Poulsen et al. — found no benefit in obese but otherwise healthy adults.
A notable concern emerged from research by Olsen et al. (2013) in the Journal of Physiology, which found that resveratrol supplementation blunted some of the cardiovascular adaptations to exercise in older men. This generated significant discussion about whether resveratrol might interfere with exercise-induced benefits in certain populations. Subsequent research has not uniformly replicated this finding, and the debate continues.
On the longevity side, the mouse lifespan extension studies from Sinclair’s group (Baur et al., 2006 in Nature) showed resveratrol significantly extended healthy lifespan in high-fat-diet-fed mice. Whether these effects translate to healthy humans on normal diets remains unproven.
Pterostilbene: Less Human Data, More Consistent Metabolic Results
Pterostilbene has a smaller but more consistent human evidence base, primarily focused on metabolic and cognitive outcomes. The Riche et al. (2013) clinical trial in Journal of Toxicology found significant reductions in blood pressure with pterostilbene at 100–200 mg/day over 6–8 weeks in adults with elevated baseline blood pressure. LDL cholesterol effects were less consistent across studies.
Animal research on pterostilbene and cognition is particularly interesting. Studies in rodents have shown improvements in learning and memory, with evidence of reduced oxidative stress in brain tissue. Whether this extends meaningfully to humans is not yet established through large trials, but pterostilbene’s superior blood-brain barrier penetration (a consequence of its lipophilicity) makes it a plausible candidate for neurological applications where resveratrol’s poor bioavailability would limit access.
Cancer Research
Both compounds have been studied extensively in cancer cell lines and animal models, with evidence of anti-proliferative and pro-apoptotic effects across multiple cancer types. Neither has clinical evidence establishing a role in human cancer prevention or treatment, and it would be premature to use either compound for that purpose. The cell and animal work is mechanistically interesting; the clinical gap is large.
Safety Profiles
Both compounds have reasonable safety records within normal supplemental dose ranges, with some distinctions worth noting.
Resveratrol is generally well-tolerated at doses up to 1,000–2,000 mg/day in clinical trials, with gastrointestinal discomfort (nausea, diarrhea) as the most common adverse effect at higher doses. There is some evidence of hormonal effects at high doses — resveratrol has estrogen receptor activity — which warrants caution for individuals with hormone-sensitive conditions. If you take prescription medications, note that resveratrol inhibits CYP3A4 and CYP2C9, potentially affecting drug metabolism. Consult a healthcare provider before combining with medications processed by these pathways.
Pterostilbene’s safety data is more limited due to its shorter history as a supplement. The Riche et al. trial found increased LDL cholesterol in some participants at the 250 mg/day dose — a finding that has not been explained and warrants attention at higher doses. Below 200 mg/day, no clinically meaningful safety signals have emerged in published trials. Its own estrogenic activity is lower than resveratrol’s, though it is not absent.
Neither compound has been adequately studied in pregnancy, and both are best avoided in that context.
Dosage
Given the bioavailability difference, the effective dose ranges differ substantially:
- Resveratrol: Most human trials use 150–1,000 mg/day. David Sinclair has publicly discussed taking 1,000 mg/day. The common dosing recommendation in longevity stacks is 500–1,000 mg/day of trans-resveratrol (the active isomer — check labels). Always take with a fatty meal or fat-containing foods to maximize absorption. Micronized or liposomal formulations improve bioavailability over standard powder.
- Pterostilbene: Effective doses in human studies range from 50–250 mg/day. Most longevity-focused protocols use 50–150 mg/day. The higher bioavailability means less is needed for comparable systemic exposure. The LDL concern from one trial at 250 mg/day is worth noting — staying at or below 150 mg/day is the more conservative approach.
Pterostilbene vs. Resveratrol: How to Choose
The honest answer is that the evidence does not clearly declare a winner. Resveratrol has more human data behind it; pterostilbene has better pharmacokinetics and a signal that its smaller doses may deliver more active compound. Here is how to think about the decision:
Choose resveratrol if: you want the compound with the larger human clinical evidence base; you are following a Sinclair-influenced stack protocol where resveratrol is explicitly paired with NMN; or you prefer the longer track record of safety data. Use a quality trans-resveratrol supplement, take it with fat, and consider a micronized formulation. For more on why resveratrol and NMN are so often combined, see the article on NMN + resveratrol stacking.
Choose pterostilbene if: you want theoretically higher systemic exposure per milligram; you are primarily interested in blood pressure or cognitive applications; or you are looking for a lower-dose option that achieves comparable tissue levels. The smaller evidence base is a real limitation, but the pharmacokinetic case for pterostilbene is strong.
Take both if: you are building a comprehensive stack and want to cover both stilbene pathways. They are not redundant — the bioavailability and half-life differences mean they are not simply duplicating each other, and their combined effect on SIRT1 and AMPK pathways may be additive. Many longevity stacks include low-dose pterostilbene (50–100 mg) alongside resveratrol (500 mg) rather than choosing one or the other.
Frequently Asked Questions
Is pterostilbene just a better version of resveratrol?
In terms of bioavailability and pharmacokinetics, pterostilbene has clear advantages. But “better” depends on what you are optimizing for. Resveratrol has been studied in far more human trials, and its metabolites — though less active than the parent compound — are not inert. Pterostilbene’s stronger pharmacokinetics do not automatically translate to stronger clinical outcomes in humans; that question is still being answered. The more accurate framing is that pterostilbene is a bioavailability-optimized structural analog, not a straightforward upgrade.
Can I take pterostilbene and resveratrol together?
Yes. There are no known adverse interactions between them. Combination products exist, though you can also source them separately. If combining, consider reducing individual doses slightly — for example, 500 mg resveratrol plus 50 mg pterostilbene — rather than taking full doses of both.
Why does resveratrol need to be taken with fat?
Resveratrol is poorly water-soluble, and its intestinal absorption is meaningfully improved when co-ingested with dietary fat. Studies have shown substantially higher plasma resveratrol concentrations when taken with a fat-containing meal or with an oil-based supplement. This is one of the practical steps that can partly compensate for its low baseline bioavailability.
What is trans-resveratrol, and does it matter?
Resveratrol exists in two isomeric forms: trans-resveratrol and cis-resveratrol. Trans-resveratrol is the biologically active form studied in research. Cis-resveratrol is less active and converts to trans-resveratrol only partially. Quality supplements specify trans-resveratrol on the label; always verify this before buying.
Does resveratrol interfere with exercise benefits?
A 2013 study raised this concern, finding reduced VO2 max improvements and blunted cardiovascular adaptations in older men taking resveratrol alongside an exercise program. Subsequent studies have not consistently replicated this. The current evidence does not establish that resveratrol reliably blunts exercise benefits, but the question is unresolved. Individuals for whom exercise adaptation is a primary goal may want to monitor this and consider timing supplementation away from workouts.